TAIPEI, TAIWAN - Media OutReach- November 5, 2018 - Insilico Medicine, a Rockville-based company developing anend-to-end drug discovery pipeline utilizing next-generation artificialintelligence (AI), was invited to speak at the 6th Healthcare and Life SciencesLeadership Summit, held on November first and second in Shanghai, China. 

ChinaRenaissance's 6th Healthcare and Life Sciences Leadership Summit - Therole of AI in driving innovation and transformation of the healthcare sector. (From left: Zhi Xiao, Director of China's State Development & InvestmentCorporation (SDIC), moderator of this session; Artur Kadurin, Chief AI Officerof Insilico Medicine and CEO of Insilico Taiwan; Xing He, Partner of HighlightCapital; Shigong Kong, Vice President of Beijing Allcure Medical; Lipeng Lai,co-founder of Big Data R&D atXtalPl; and Shaodian Zhang, founder and CEO of Synyi AI)

The Summit is hosted by China Renaissance Group, a leading investmentbank with investments in high-growth sectors including technology andhealthcare, and is one of China's most prestigious annual events.  Over the course of this year's two-dayprogram, which included three keynote speeches, 16 panel sessions and 16roadshow presentations, hundreds of leaders from the global biomedicine andhealthcare sectors shared their latest insights and analysis on current trendsand the state of the industry. 

Artur Kadurin, Chief AIOfficer of Insilico Medicine and CEO of Insilico Taiwan, was invited to presenton the opening day of the Summit, at the session titled, "The role of AI indriving innovation and transformation of the healthcare sector."  The session was moderated by Zhi Xiao, Directorof China's State Development & Investment Corporation (SDIC), and featuredpanelists Xing He, Partner of Highlight Capital; Shigong Kong, Vice Presidentof Beijing Allcure Medical; Lipeng Lai, co-founder of Big Data R&D atXtalPl; and Shaodian Zhang, founder and CEO of Synyi AI. The group ofdistinguished panelists discussed the key role that AI is playing as the newdriver transforming the future of healthcare from the perspective of industry,academia.

Moderator Zhi Xiao noted thatChina's capital markets were very hot in the first half of the year, butexperienced a dramatic slowdown in the second half.  Nevertheless, the "AI" topic, hot since 2017,remains so and is "the" keyword for VC and PE investment, especially in thefields of biomedicine and healthcare. Recent data revealed that at least 31 AIcompanies have successfully completed 34 rounds of fundraising, totalingover US $400 million raised.

AI has been through threemajor ups and downs since the 1960s. Most recently, technology breakthroughs in pattern recognition have shownthe greatest promise in future applications in therapeutics and diagnosis.  Artur Kadurin, Chief AI Officer of InsilicoMedicine and CEO of Insilico Taiwan said: "AI has had great success in computervision and now outperforms humans. For example, we can currentlyapply AI to image pattern recognition for cancer screening."  Many new AI applications in biomedicine andhealthcare have also been developed rapidly, such as drug discovery, roboticscare, electronic health records, precision diagnosis and therapy, and telemedicine.

In support of Mr. Kadurin's viewpoint, Beijing Allcure Medical recentlyreceived an investment of over RMB 700 million from a state-owned fund.  This is the first time that China's statefunds have been invested in a corporate platform focused on leveraging AI inradiation therapy for cancer.  Additionally,Highlight Capital also invested in a number of startups using AI in moleculardiagnosis and gene sequencing.  In short,investment trends suggest that patient-doctor interactions and hospital operationsare being completely revolutionized as AI successfully masters precision diagnosis. 

As human life expectancy continues to increase, aging well has become one of the newest and hottesttopics in healthcare today. Insilico Medicine has invested a great deal ofeffort in anti-aging studies using AI.  Mr.Kadurin emphasized, "Since the rise of deep learning, AI systemshave shown great potential and have outperformed humans in many health-relatedfields.  I think it's time to use AI forcreating super-man health."

About Insilico Medicine, Inc.

Insilico Medicine is an artificialintelligence company with R&D offices and resources in the US, Belgium,Russia, the UK, Taiwan and Korea, sourced through hackathons and competitions.The company and its scientists are dedicated to extending human productivelongevity and transforming every step of the drug discovery and drugdevelopment process through excellence in biomarker discovery, drugdevelopment, digital medicine and aging research.

Insilico pioneered the applications of thegenerative adversarial networks (GANs) and reinforcement learning forgeneration of novel molecular structures for diseases with a known ligand andwith no known targets. In addition to working collaborations with largepharmaceutical companies, the company is pursuing internal drug discoveryprograms in cancer, dermatological diseases, fibrosis, Parkinson's Disease,Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through apartnership with LifeExtension.com the company launched a range ofnutraceutical products, compounded using advanced bioinformatics and deeplearning techniques. It also provides a range of consumer-facing applications,including Young.AI.

In 2017, NVIDIA selected Insilico Medicine asone of the Top 5 AI companies for potential in social impact. In 2018, thecompany was named one of the global top 100 AI companies by CB Insights. In2018 it received the Frost & Sullivan 2018 North American ArtificialIntelligence for Aging Research and Drug Development Award accompanied byindustry brief.

Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8

https://www.insilico.com

Contact Information

Roger Lai, Consultant

jclai@swem.com.tw